Database Query Results : , , PSA

PSA, prostate-specific antigen: Click to Expand ⟱
Source:
Type:
Prostate-Specific Antigen (PSA) is a protein produced by both normal and malignant cells of the prostate gland. PSA testing is commonly used as a screening tool for prostate cancer.
Elevated levels of PSA in the blood can indicate the presence of prostate cancer, but they can also be caused by other conditions, such as benign prostatic hyperplasia (BPH) or prostatitis (inflammation of the prostate).

PSA is a clinical biomarker.
Scientific Papers found: Click to Expand⟱
287- ALA,  HCA,  Lyco,    Metabolic treatment of cancer: intermediate results of a prospective case series
PSA↓, OS↑,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
207- Api,    Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells
- in-vitro, Pca, LNCaP
PSA↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, P21↑, AR↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4624- Bor,  VitD3,    Boron as a Medicinal Ingredient in Oral Natural Health Products
- Review, Pca, NA
*Half-Life↝, *eff↑, PSA↓, TumVol↓, IGF-1↓, *memory↓, *motorD↓,
696- Bor,    Nothing Boring About Boron
- Review, Var, NA
*hs-CRP↓, *TNF-α↓, *SOD↑, *Catalase↑, *GPx↑, *cognitive↑, *memory↑, *Risk↓, *SAM-e↑, *NAD↝, *ATP↝, *Ca+2↝, HDAC↓, TumVol↓, IGF-1↓, PSA↓, Cyc↓, TumCMig↓, *serineP↓, HIF-1↓, *ChemoSideEff↓, *VitD↑, *Mag↑, *eff↑, Risk↓, *Inflam↓, *neuroP↑, *Calcium↑, *BMD↑, *chemoP↑, AntiCan↑, *Dose↑, *Dose↝, *BMPs↑, *testos↑, angioG↓, Apoptosis↑, *selectivity↑, *chemoPv↑,
704- Bor,    Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid
- in-vitro, Pca, NA
PSA↓,
746- Bor,    Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope
- Review, NA, NA
eff↑, *toxicity↓, ROS↑, LAT↓, AntiCan↑, AR↓, PSMB5↓, IGF-1↓, PSA↓, TumVol↓, eff↑, Rho↓, Cdc42↓, Ca+2↓, eff↑,
706- Bor,    Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice
- in-vivo, Pca, LNCaP
TumVol↓, IGF-1↓, PSA↓,
708- Bor,    Boron containing compounds as protease inhibitors
PSA↓,
726- Bor,    Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open
- Review, NA, NA
NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,
3518- Bor,    Boron Report
- Review, Var, NA - Review, AD, NA
Risk↓, serineP↓, PSA↓, TumVol↓, IGF-1↓, *Mag↑, *Calcium↑, *VitD↑, *COX2↓, *5LO↓, *PGE2↓, *NF-kB↓, *cognitive↑,
145- CA,  CUR,    The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, PC, DU145
AR↓, ARE/EpRE↑, TumCP↓, PSA↓,
2013- CAP,    Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, P53↑, P21↑, BAX↑, PSA↓, AR↓, NF-kB↓, Proteasome↓, TumVol↓, eff∅,
142- CUR,    Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts
- in-vivo, Pca, LNCaP
AR↓, PSA↓,
151- CUR,    Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓, PSA↓, Dose↑,
153- CUR,    Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo
- in-vivo, Pca, C4-2B
PSA↓, TGF-β↓, BMPs↑, TumMeta↓,
120- CUR,    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
- Human, Pca, NA
PSA↓, Dose↝,
122- CUR,  isoFl,    Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen
- Human, Pca, LNCaP
PSA↓, AR↓,
15- CUR,  UA,    Effects of curcumin and ursolic acid in prostate cancer: A systematic review
- Review, Pca, NA
NF-kB↝, Akt↝, AR↝, Apoptosis↝, Bcl-2↝, Casp3↝, BAX↝, P21↝, ROS↝, Bcl-xL↝, JNK↝, MMP2↝, P53↝, PSA↝, VEGF↝, COX2↝, cycD1/CCND1↝, EGFR↝, IL6↝, β-catenin/ZEB1↝, mTOR↝, NRF2↝, AP-1↝, Cyt‑c↝, PI3K↝, PTEN↝, Cyc↝, TNF-α↝,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
2179- itraC,    Repurposing itraconazole for the treatment of cancer
- Review, Var, NA
HH↓, angioG↓, TumCCA↑, MDR1↓, P-gp↓, mTOR↓, VEGF↓, Smo↓, Gli1↓, OS↑, PSA↓,
5115- JG,    Natural Products to Fight Cancer: A Focus on Juglans regia
- Review, Var, NA
Casp3↑, Casp9↑, MMP↓, AR↓, PSA↓, E-cadherin↑, N-cadherin↓, Vim↓, Akt↓, GSK‐3β↓, EMT↑, TumCI↓, MMP9↓, VEGF↓, MMP2↓, TumCCA↑, ROS↑, Apoptosis↑, GSH↓, Catalase↓, SOD↓, GPx↓, DNAdam↑, γH2AX↑, eff↑, BAX↑, Fas↑, Pin1↓,
3281- Lyco,  Chemo,    Lycopene Supplementation for Patients Under Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Review, Var, NA
eff↑, cardioP↑, eff?, PSA↓, RenoP↑,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
4780- Lyco,    Potential inhibitory effect of lycopene on prostate cancer
- Review, Pca, NA
TumCP↓, TumCCA↑, Apoptosis↑, *neuroP↑, *NF-kB↓, *JNK↓, *NRF2↑, *BDNF↑, *Ca+2↝, *antiOx↑, *AntiCan↑, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *TNF-α↓, NF-kB↓, DNAdam↓, PSA↓, P53↓, cycD1/CCND1↓, NRF2↓, Akt2↓, PPARγ↓,
4647- OLEC,    Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer
- Review, Var, NA
*Inflam↓, AntiCan↑, *COX2↓, *ROS↓, *TNF-α↓, *IL1β↓, *iNOS↓, TumCP↓, *AntiAg↑, mTOR↓, STAT3↓, ERK↓, p‑Akt↓, Bcl-2↓, ROS↑, PSA↓,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- Review, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓, TumCCA↑, ROS↑, miR-21↓, TumCP↓, selectivity↑, PDGF↓, EGF↓, TNF-α↓, VEGFR2↓, mTOR↓, cMyc↓, MMPs↓, GRP78/BiP↑, CHOP↑,
70- QC,    Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
PSA↓, AR↓, NKX3.1↓, HK2↓,
82- QC,  ATG,    Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells
- in-vitro, Pca, LNCaP
AR↓, PI3K/Akt↓, miR-21↓, STAT3↓, BAD↓, PRAS40↓, GSK‐3β↓, PSA↓, NKX3.1↑, Bax:Bcl2↑, miR-19b↓, miR-148a↓, AMPKα↓, TumCP↓, chemoPv↑, TumCMig↓,
75- QC,  ENZ,    Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells
- in-vitro, Pca, HEK293 - in-vitro, NA, 22Rv1 - in-vitro, NA, C4-2B
hnRNPA1↓, PSA↓, NKX3.1↓, FKBP5↓, UBE2C↓, AR-FL↓, AR-V7↑, AR↓, eff↑, TumVol↓, BioAv↓,
3055- RES,    Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27↑, TumCCA↑, ChemoSen↑, COX2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,
3063- RES,    Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiAg↑, *chemoPv↑, ChemoSen↑, BioAv↑, Half-Life↝, COX2↓, cycD1/CCND1↓, CDK2↓, CDK4↓, CDK6↓, P21↑, MMP9↓, NF-kB↓, Telomerase↓, PSA↓, MAPK↑, P53↑,
3002- RosA,    Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols
- Review, Var, NA
TumCG↓, TumCP↓, TumCCA↑, ChemoSen↑, NRF2↑, PERK↑, SESN2↑, HO-1↑, cl‑Casp3↑, ROS↑, UPR↑, ER Stress↑, CHOP↑, HER2/EBBR2↓, ER-α36↓, PSA↓, BAX↑, AR↓, P-gp↓, Cyt‑c↑, HSP70/HSPA5↑, eff↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, cl‑PARP↑, eff↑,
3033- RosA,    Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP - vitro+vivo, NA, NA
ER Stress↑, selectivity↑, AR↓, TumCG↓, TumCCA↑, CHOP↑, PERK↓, GRP78/BiP↑, PSA↓,
2446- SFN,  CAP,    The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor
- in-vitro, Pca, LNCaP
AR↓, Bcl-xL↓, TumCP↓, Glycolysis↓, HK2↓, PKA↓, Hif1a↓, PSA↓, ECAR↓, BioAv↑, BioAv↓, *toxicity↓,
1509- SFN,    Combination therapy in combating cancer
- Review, NA, NA
NRF2↑, ChemoSideEff↓, eff↑, TumCP↓, Apoptosis↑, TumCCA↑, eff↑, PSA↓, P53↑, Hif1a↓, CAIX↓, chemoR↓, 5HT↓,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
616- VitC,    Suppression of alkaline phosphatase in prostate cancer patients by high dose intravenous Vitamin C Treatment: Three cases
- Case Report, NA, NA
PSA↓, ALP↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 42

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ARE/EpRE↑, 1,   Catalase↓, 2,   Catalase↑, 1,   CYP1A1↓, 1,   GPx↓, 1,   GPx↑, 2,   GSH↓, 5,   GSH↑, 1,   HO-1↑, 2,   MDA↓, 1,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 4,   NRF2↝, 1,   ROS↓, 1,   ROS↑, 11,   ROS⇅, 1,   ROS↝, 1,   SAM-e↝, 1,   SOD↓, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   EGF↓, 1,   p‑MEK↓, 1,   MMP↓, 4,  

Core Metabolism/Glycolysis ⓘ

CAIX↓, 1,   cMyc↓, 4,   ECAR↓, 1,   FASN↓, 1,   Glycolysis↓, 2,   HK2↓, 3,   LAT↓, 1,   NAD↝, 1,   PI3K/Akt↓, 1,   PI3K/Akt↝, 1,   PPARγ↓, 1,   PPARγ↑, 1,   PSMB5↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↝, 1,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 6,   Apoptosis↝, 1,   BAD↓, 1,   BAX↑, 6,   BAX↝, 1,   Bax:Bcl2↑, 2,   Bcl-2↓, 5,   Bcl-2↝, 1,   Bcl-xL↓, 2,   Bcl-xL↝, 1,   BID↑, 1,   Casp↑, 2,   Casp3↑, 4,   Casp3↝, 1,   cl‑Casp3↑, 4,   cl‑Casp7↑, 2,   cl‑Casp8↑, 2,   Casp9↑, 3,   cl‑Casp9↑, 2,   CK2↓, 2,   Cyt‑c↑, 5,   Cyt‑c↝, 1,   DR5↑, 1,   Fas↑, 1,   cl‑IAP2↑, 1,   iNOS↓, 1,   JNK↝, 1,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 1,   MAPK↝, 1,   p27↑, 4,   Proteasome↓, 1,   survivin↓, 1,   Telomerase↓, 3,  

Kinase & Signal Transduction ⓘ

AMPKα↓, 1,   HER2/EBBR2↓, 2,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   miR-21↓, 3,   p‑pRB↓, 2,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↑, 3,   eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 2,   HSP70/HSPA5↑, 1,   HSPs↓, 1,   PERK↓, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

SESN2↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   DNAdam↑, 1,   NKX3.1↓, 2,   NKX3.1↑, 1,   P53↓, 2,   P53↑, 6,   P53↝, 1,   PARP↑, 1,   cl‑PARP↑, 3,   PARP1↑, 1,   PCNA↓, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 4,   CDK4↓, 6,   Cyc↓, 2,   Cyc↝, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   cycD1/CCND1↝, 1,   cycE/CCNE↓, 2,   P21↓, 1,   P21↑, 9,   P21↝, 1,   RB1↑, 1,   TumCCA↑, 13,  

Proliferation, Differentiation & Cell State ⓘ

AR-FL↓, 1,   AR-V7↑, 1,   BRAF↝, 1,   CD44↓, 1,   EMT↓, 2,   EMT↑, 1,   ERK↓, 4,   p‑ERK↓, 1,   FOXO3↓, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   p‑GSK‐3β↓, 1,   HDAC↓, 2,   HH↓, 1,   IGF-1↓, 8,   IGFBP3↑, 2,   mTOR↓, 3,   mTOR↝, 1,   p‑mTOR↓, 2,   NOTCH↓, 1,   NOTCH1↓, 1,   p‑P70S6K↓, 1,   PI3K↓, 2,   PI3K↝, 1,   PTEN↑, 1,   PTEN↝, 2,   Shh↓, 1,   Smo↓, 1,   STAT3↓, 4,   TumCG↓, 5,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

5LO↓, 1,   Akt2↓, 1,   AntiAg↑, 1,   AP-1↝, 1,   CA↓, 1,   Ca+2↓, 1,   Ca+2↑, 2,   cal2↑, 1,   Cdc42↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 4,   ER-α36↓, 1,   FAK↓, 2,   hnRNPA1↓, 1,   ITGB4↓, 1,   miR-148a↓, 1,   miR-19b↓, 1,   miR-203↑, 1,   MMP2↓, 3,   MMP2↝, 1,   MMP7↓, 1,   MMP9↓, 5,   MMPs↓, 2,   N-cadherin↓, 2,   PDGF↓, 2,   PKA↓, 1,   Rho↓, 1,   serineP↓, 1,   TGF-β↓, 2,   TumCI↓, 2,   TumCMig↓, 5,   TumCP↓, 10,   TumMeta↓, 2,   uPA↓, 1,   Vim↓, 2,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↝, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ATF4↑, 1,   EGFR↓, 4,   EGFR↝, 1,   HIF-1↓, 1,   Hif1a↓, 8,   LOX1↓, 1,   VEGF↓, 10,   VEGF↝, 1,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

NHE1↓, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 5,   COX2↝, 1,   CXCR4↓, 1,   IFN-γ↓, 1,   IL1↓, 4,   IL10↑, 1,   IL1β↓, 1,   IL4↑, 1,   IL6↓, 3,   IL6↝, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 7,   NF-kB↝, 1,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 40,   PSA↝, 1,   PSA∅, 1,   TNF-α↓, 4,   TNF-α↝, 1,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 19,   AR↝, 1,   CDK6↓, 1,   FKBP5↓, 1,   GR↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 9,   BioAv↑, 4,   chemoR↓, 1,   ChemoSen↑, 7,   Dose↑, 5,   Dose↝, 2,   eff?, 1,   eff↑, 15,   eff↝, 1,   eff∅, 1,   Half-Life↓, 2,   Half-Life↝, 4,   MDR1↓, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

ALP↓, 1,   AR↓, 19,   AR↝, 1,   BMPs↑, 1,   BRAF↝, 1,   EGFR↓, 4,   EGFR↝, 1,   HER2/EBBR2↓, 2,   IL6↓, 3,   IL6↝, 1,   PD-L1↓, 1,   PSA↓, 40,   PSA↝, 1,   PSA∅, 1,  

Functional Outcomes ⓘ

AntiCan↑, 7,   cardioP↑, 2,   chemoP↑, 2,   chemoPv↑, 2,   ChemoSideEff↓, 1,   hepatoP↑, 2,   OS↑, 4,   Pain↓, 1,   Pin1↓, 1,   PRAS40↓, 1,   QoL↑, 1,   RenoP↑, 1,   Risk↓, 2,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 8,   UBE2C↓, 1,  
Total Targets: 278

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 5,   Catalase↑, 1,   GPx↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 1,   SAM-e↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↝, 1,  

Core Metabolism/Glycolysis ⓘ

NAD↝, 1,   SIRT1↑, 1,  

Cell Death ⓘ

iNOS↓, 1,   JNK↓, 1,   MAPK↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1↓, 1,   IGFBP3↑, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 2,   Ca+2↝, 2,   PKCδ↓, 1,   serineP↓, 1,   TIMP1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1↓, 1,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 2,   Inflam↓, 7,   NF-kB↓, 2,   PGE2↓, 1,   TNF-α↓, 3,   VitD↑, 2,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Hormonal & Nuclear Receptors ⓘ

testos↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↑, 1,   Dose↝, 1,   eff↑, 2,   Half-Life↝, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

BMD↑, 1,   BMPs↑, 1,   Calcium↑, 2,   hs-CRP↓, 1,   IL6↓, 1,   Mag↑, 2,   VitD↑, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 1,   chemoPv↑, 2,   ChemoSideEff↓, 1,   cognitive↑, 2,   memory↓, 1,   memory↑, 1,   motorD↓, 1,   neuroP↑, 2,   Risk↓, 1,   toxicity↓, 3,  
Total Targets: 57

Scientific Paper Hit Count for: PSA, prostate-specific antigen
8 Boron
7 Curcumin
4 Lycopene
4 Quercetin
2 Apigenin (mainly Parsley)
2 Capsaicin
2 Resveratrol
2 Rosmarinic acid
2 Sulforaphane (mainly Broccoli)
2 Silymarin (Milk Thistle) silibinin
1 Alpha-Lipoic-Acid
1 HydroxyCitric Acid
1 Astaxanthin
1 Vitamin D3
1 Carnosic acid
1 isoflavones
1 Ursolic acid
1 EGCG (Epigallocatechin Gallate)
1 itraconazole
1 Juglone
1 Chemotherapy
1 Oleocanthal
1 Arctigenin
1 enzalutamide
1 Selenite (Sodium)
1 Radiotherapy/Radiation
1 Aflavin-3,3′-digallate
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:264  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page